# EDGAR Filing Document

**Accession Number:** 0001838003
**File Stem:** 0001104659-26-039715
**Filing Date:** 2026-4
**Character Count:** 36151
**Document Hash:** 1bda86b516db83f2113093645f1546b0
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-26-039715.hdr.sgml**: 20260406

**ACCESSION NUMBER**: 0001104659-26-039715

**CONFORMED SUBMISSION TYPE**: S-1/A

**PUBLIC DOCUMENT COUNT**: 12

**FILED AS OF DATE**: 20260406

**DATE AS OF CHANGE**: 20260403

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Encore Medical, Inc.
- **CENTRAL INDEX KEY:** 0001838003
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 822906303
- **STATE OF INCORPORATION:** MN
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-1/A
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-290244
- **FILM NUMBER:** 26839454

**BUSINESS ADDRESS:**
- **STREET 1:** 2975 LONE OAK DRIVE
- **CITY:** EAGAN
- **STATE:** MN
- **ZIP:** 55121
- **BUSINESS PHONE:** 651-797-0913

**MAIL ADDRESS:**
- **STREET 1:** 2975 LONE OAK DRIVE
- **CITY:** EAGAN
- **STATE:** MN
- **ZIP:** 55121

#### REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON APRIL 3, 2026

#### Registration No. 333-290244

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION

#### Washington, D.C. 20549

#### AMENDMENT NO. 4 TO

### FORM S-1

#### REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

### ENCORE MEDICAL, INC.
(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Minnesota** <br> (State or other jurisdiction of <br> incorporation or organization)  | **3841** <br> (Primary Standard Industrial <br> Classification Code Number)  | **82-2906303** <br> (I.R.S. Employer <br> Identification Number)  |

---

#### 2975 Lone Oak Drive, Suite 140 Eagan, MN 55121 Telephone: (651) 797-0913
(Address, including zip code, and telephone number, including area code, of registrant's principal executive offices)

#### Joseph A. Marino President and Chief Executive Officer Encore Medical, Inc. 2975 Lone Oak Drive, Suite 140 Eagan, MN 55121 Telephone: (651) 797-0913
(Name, address, including zip code, and telephone number, including area code, of agent for service)

#### Copies to:

---

| | |
|:---|:---|
| **Amy Bowler <br> Holland & Hart LLP <br> 555 17<sup>th</sup> Street, Suite 3200 <br> Denver, CO 80202 <br> Telephone: (303) 295-8000**  | **William M. Mower <br> Andrew M. Tataryn <br> Maslon LLP <br> 225 South 6<sup>th</sup> Street, Suite 2900 <br> Minneapolis, MN 55402 <br> Telephone: (612) 672-8381**  |

---

#### APPROXIMATE DATE OF COMMENCEMENT OF PROPOSED SALE TO THE PUBLIC: AS SOON AS PRACTICABLE AFTER THE EFFECTIVE DATE OF THIS REGISTRATION STATEMENT.
If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box. ☐

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company," in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐ Accelerated filer ☐ <br> Non-accelerator filer ☒ Smaller reporting company ☒ <br> Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

 **The Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933, as amended, or until the Registration Statement shall become effective on such date as the Commission, acting pursuant to said Section 8(a), may determine.** 

------

#### Explanatory Note
This Amendment No. 4 (this "Amendment") to the Registration Statement on Form S-1 of Encore Medical, Inc. (File No. 333-290244) (the "Registration Statement") is being filed as an exhibit-only filing to file an amended Filing Fee Table, filed herewith as Exhibit 107, and to add Exhibit 4.3. Accordingly, this Amendment consists only of the facing page, this explanatory note, Item 16 of Part II of the Registration Statement, the signature page to the Registration Statement, Exhibit 4.3 and Exhibit 107. The prospectus and the balance of Part II of the Registration Statement are unchanged and have been omitted.

------

#### Item 16. Exhibits and Financial Statement Schedules
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (a) Exhibits. The following exhibits are included herein or incorporated herein by reference:

---

| | |
|:---|:---|
| **Exhibit <br> Number**  | **Description**  |
| 1.1◊  | [Form of Underwriting Agreement.](https://www.sec.gov/Archives/edgar/data/1838003/000110465925125214/tm2525595d4_ex1-1.htm)  |
| 3.2◊  | [Amended and Restated Articles of Incorporation of Registrant, effective November 17, 2025.](https://www.sec.gov/Archives/edgar/data/1838003/000110465925125214/tm2525595d4_ex3-2.htm)  |
| 3.3◊  | [Amendment to the Amended and Restated Articles of Incorporation of Registrant, effective November 17, 2025.](https://www.sec.gov/Archives/edgar/data/1838003/000110465925125214/tm2525595d4_ex3-3.htm)  |
| 3.4◊  | [Bylaws of Registrant, effective December 1, 2017.](https://www.sec.gov/Archives/edgar/data/1838003/000110465925125214/tm2525595d4_ex3-4.htm)  |
| 3.5◊  | [Amended and Restated Bylaws of the Registrant, effective February 23, 2026.](http://www.sec.gov/Archives/edgar/data/1838003/000110465926022408/tm2525595d7_ex3-5.htm)  |
| 4.1◊  | [Form of Registrant's Common Stock Certificate.](https://www.sec.gov/Archives/edgar/data/1838003/000110465925089675/tm2525595d2_ex4-1.htm)  |
| 4.2◊  | [Form of Underwriters' Warrant.](https://www.sec.gov/Archives/edgar/data/1838003/000110465925089675/tm2525595d2_ex4-2.htm)  |
| 4.3  | [Form of 2021 – 2022 Investor's Warrant](tm2525595d16_ex4-3.htm) |
| 5.1◊  | [Opinion of Holland & Hart LLP.](https://www.sec.gov/Archives/edgar/data/1838003/000110465926033796/tm2525595d10_ex5-1.htm)  |
| 10.1◊  | [Contract Sales and Manufacturing Agreement, by and between Cardia, Inc. and Registrant, effective November 15, 2024, and related addenda dated December 12, 2025.](https://www.sec.gov/Archives/edgar/data/1838003/000110465925125214/tm2525595d4_ex10-1.htm)  |
| 10.2◊  | [Commercial Lease, by and between The Waters HM LLC and Registrant, effective February 3, 2023.](https://www.sec.gov/Archives/edgar/data/1838003/000110465925125214/tm2525595d4_ex10-2.htm)  |
| 10.3◊  | [First Amendment to Commercial Lease, by and between The Waters HM LLC and Registrant, effective March 3, 2023.](https://www.sec.gov/Archives/edgar/data/1838003/000110465925125214/tm2525595d4_ex10-3.htm)  |
| 10.4◊  | [Loan Agreement, by and between Merit Medical Systems, Inc. and Registrant, dated November 6, 2023.](https://www.sec.gov/Archives/edgar/data/1838003/000110465925125214/tm2525595d4_ex10-4.htm)  |
| 10.4(a)◊ †  | [Encore Medical, Inc. 2018 Stock Incentive Plan.](https://www.sec.gov/Archives/edgar/data/1838003/000110465925125214/tm2525595d4_ex10-4a.htm)  |
| 10.4(b)◊ †  | [Form of Incentive Stock Option Agreement under the 2018 Stock Incentive Plan.](https://www.sec.gov/Archives/edgar/data/1838003/000110465925125214/tm2525595d4_ex10-4b.htm)  |
| 10.4(c)◊ †  | [Form of Nonqualified Stock Option Award Agreement under the 2018 Stock Incentive Plan.](https://www.sec.gov/Archives/edgar/data/1838003/000110465925125214/tm2525595d4_ex10-4c.htm)  |
| 10.5◊  | [Security Agreement, by and between Merit Medical Systems, Inc. and Registrant, dated November 6, 2023.](https://www.sec.gov/Archives/edgar/data/1838003/000110465925089675/tm2525595d2_ex10-5.htm)  |
| 10.6◊  | [Independent Contractor Agreement, by and between Registrant and Gregory Steiner, dated December 15, 2024.](https://www.sec.gov/Archives/edgar/data/1838003/000110465926033796/tm2525595d10_ex10-7.htm)  |
| 10.7◊  | [Amended and Restated Convertible Promissory Note, by and between Christopher J. Turnbull and Registrant, dated November 24, 2025.](https://www.sec.gov/Archives/edgar/data/1838003/000110465925125214/tm2525595d4_ex10-7.htm)  |
| 10.8◊  | [Convertible Promissory Note, by and between Joseph A. Marino and Registrant, dated November 24, 2025.](https://www.sec.gov/Archives/edgar/data/1838003/000110465925125214/tm2525595d4_ex10-8.htm)  |
| 10.9◊  | [Convertible Promissory Note, by and between 1915 Florida Investment Corp. and Registrant, dated December 10, 2025.](https://www.sec.gov/Archives/edgar/data/1838003/000110465925125214/tm2525595d4_ex10-9.htm)  |
| 10.10◊  | [Loan Agreement, by and among Cardia, Inc. and Registrant, dated May 15, 2025.](http://www.sec.gov/Archives/edgar/data/1838003/000110465926022408/tm2525595d7_ex10-10.htm)  |
| 23.1◊  | [Consent of Boulay PLLP, Independent Registered Public Accounting Firm.](https://www.sec.gov/Archives/edgar/data/1838003/000110465926033796/tm2525595d10_ex23-1.htm)  |
| 23.2◊  | [Consent of Holland & Hart LLP (contained in Exhibit 5.1).](https://www.sec.gov/Archives/edgar/data/1838003/000110465926033796/tm2525595d10_ex5-1.htm)  |
| 24.1◊  | [Power of Attorney (included on signature page of initial Registration Statement).](https://www.sec.gov/Archives/edgar/data/1838003/000110465925089675/tm2525595-1_s1.htm#tPOA)  |
| 107  | [Filing Fee Table.](tm2525595d15_ex-filingfees.htm)  |

---

†

Indicates a management contract or compensatory plan or arrangement.

◊

Previously filed.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (b) Financial Statement Schedules. All schedules have been omitted because the information required to be presented in them is not applicable or is shown in the consolidated financial statements or related notes.

------

#### SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the registrant has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Eagan, Minnesota, on this 3rd day of April 2026.

#### ENCORE MEDICAL, INC.
/s/ Joseph A. Marino

Joseph A. Marino

*President and Chief Executive Officer*

Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated:

---

| | | | |
|:---|:---|:---|:---|
| **Signature**  | **Signature**  | **Title**  | **Date**  |
| /s/ Joseph A. Marino <br>Joseph A. Marino  | /s/ Joseph A. Marino <br>Joseph A. Marino  | President, Chief Executive Officer and Director (*Principal Executive Officer*) | April 3, 2026  |
| \* <br>Scott S. Robinson  | \* <br>Scott S. Robinson  | Treasurer (*Principal Financial Officer and Principal Accounting Officer*) | April 3, 2026  |
| \* <br>Peter M. Buonomo  | \* <br>Peter M. Buonomo  | Director | April 3, 2026  |
| \* <br>Todd C. Johnson  | \* <br>Todd C. Johnson  | Director | April 3, 2026  |
| \* <br>Timothy G. Laske, PhD  | \* <br>Timothy G. Laske, PhD  | Director | April 3, 2026  |
| \* <br>Christopher J. Turnbull  | \* <br>Christopher J. Turnbull  | Director | April 3, 2026  |
| \*By: | /s/ Joseph A. Marino <br>Joseph A. Marino <br> Attorney-in-Fact  |  |  |

---

------

## Exhibit 4.3

**Exhibit 4.3**

**FORM OF INVESTOR'S WARRANT**

THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER EITHER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS AND MAY NOT BE SOLD, TRANSFERRED, ASSIGNED, OFFERED, PLEDGED OR OTHERWISE DISTRIBUTED FOR VALUE UNLESS THERE IS AN EFFECTIVE REGISTRATION STATEMENT UNDER SUCH ACT AND SUCH LAWS COVERING SUCH SECURITIES, OR THE COMPANY RECEIVES AN OPINION OF COUNSEL ACCEPTABLE TO THE COMPANY STATING THAT SUCH SALE, TRANSFER, ASSIGNMENT, OFFER, PLEDGE OR OTHER DISTRIBUTION FOR VALUE IS EXEMPT FROM THE REGISTRATION AND PROSPECTUS DELIVERY REQUIREMENTS OF SUCH ACT AND SUCH LAWS.

**<u>WARRANT</u>**

**TO PURCHASE ____________ SHARES OF COMMON STOCK** 

**OF** 

**ENCORE MEDICAL, INC.**

THIS CERTIFIES THAT, for good and valuable consideration,<u> </u> (the "<u>Investor</u>"), or its registered assigns, is entitled to subscribe for and purchase from Encore Medical, Inc., a Minnesota corporation (the "<u>Company</u>"), at any time after the date hereof up to and including 5:00 p.m. Minneapolis, Minnesota time on _________________, 2029 or such earlier date as provided in Section 5 hereof (the "<u>Expiration Date</u>"), ___________ (___) fully paid and nonassessable shares of the common stock of the Company at the price of $_____ per share (the "<u>Warrant Exercise Price</u>"). The shares which may be acquired upon exercise of this Warrant are referred to herein as the "<u>Warrant Shares</u>." As used herein, the term "<u>Holder</u>" means the Investor or any party who acquires all or a part of this Warrant as a registered transferee of the Investor. As used herein, the term "<u>common stock</u>" means and includes the Company's authorized common stock $0.01 par value, and shall also include any capital stock of any class of the Company hereafter authorized which shall not be limited to a fixed sum or percentage in respect of the rights of the holders thereof to participate in dividends or in the distribution of assets upon the voluntary or involuntary liquidation, dissolution, or winding up of the Company.

This Warrant is subject to the following provisions, terms and conditions:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. <u>Exercise; Transferability</u>. Subject to the provisions of Section 3 hereof, the rights represented by this Warrant may be exercised by the Holder hereof, in whole or in part (but not as to a fractional share of common stock), by written notice of exercise (in the form attached hereto) delivered to the Company at the principal office of the Company prior to the Expiration Date and accompanied or preceded by the surrender of this Warrant and a check in payment of the Warrant Exercise Price for the shares.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. <u>Exchange and Replacement</u>. Subject to Sections 1 and 7 hereof, this Warrant is exchangeable upon the surrender hereof by the Holder to the Company at its office for new Warrants of like tenor and date representing in the aggregate the right to purchase the number of Warrant Shares purchasable hereunder, each of the new Warrants to represent the right to purchase the number of Warrant Shares (not to exceed the aggregate total number purchasable hereunder) as designated by the Holder at the time of surrender. Upon receipt by the Company of evidence reasonably satisfactory to it of the loss, theft, destruction, or mutilation of this Warrant, and, in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it, and upon surrender and cancellation of this Warrant, if mutilated, the Company will make and deliver a new Warrant of like tenor, in lieu of this Warrant. This Warrant will be promptly canceled by the Company upon its surrender in connection with any exchange or replacement. The Company will pay all expenses, taxes (other than stock transfer taxes), and other charges payable in connection with the preparation, execution, and delivery of Warrants pursuant to this Section 2.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. <u>Issuance of the Warrant Shares</u>. The Company agrees that the Warrant Shares purchased upon exercise of this Warrant will be deemed to be issued to the Holder as of the close of business on the date on which this Warrant is exercised, surrendered and payment made for the Warrant Shares. Certificates for the Warrant Shares so purchased will be delivered to the Holder within a reasonable time, not exceeding fifteen (15) days after the Warrant has been exercised, and, unless this Warrant has expired, a new Warrant representing the right to purchase the number of Warrant Shares, if any, with respect to which this Warrant has not been exercised will also be delivered to the Holder within the time.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4. <u>Covenants of the Company</u>. The Company covenants and agrees that all Warrant Shares will, upon issuance, be duly authorized and issued, fully paid, nonassessable, and free from all taxes, liens, and charges with respect to the issue thereof except for all taxes, liens and charges imposed by the Holder. The Company further covenants and agrees that during the period within which the rights represented by this Warrant may be exercised, the Company will at all times have authorized and reserved for the purpose of issue or transfer upon exercise of the subscription rights evidenced by this Warrant a sufficient number of shares of common stock to provide for the exercise of the rights represented by this Warrant.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5. <u>Termination of Warrant upon Occurrence of Certain Events</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) In the event that the Company is subject to an Acquisition Transaction (as defined below), the Company may, in its sole discretion, terminate this Warrant, effective as of the date of the Acquisition Transaction, by delivery of notice of termination to each Holder at least fourteen days prior to the date of the Acquisition Transaction, in which case during the period from the date on when notice is delivered to the date of consummation of the public offering or Acquisition Transaction, each Holder will have the right to exercise in whole or in part any of its then outstanding Warrants, but (i) any such exercise, at the option of the Holder, may be contingent upon and subject to the occurrence of the Acquisition Transaction, and, (ii) if the Acquisition Transaction does not take place within the period specified by the Company in the termination notice, the exercise will be null and void unless the Holder agrees otherwise.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Unless the Company takes action under Section 5(a), in case of any:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;i. consolidation or merger to which the Company is a party (other than a merger or consolidation in which the Company is the continuing corporation or a merger effected exclusively for the purpose of changing the domicile of the Company),

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ii. sale or conveyance to another corporation of all or substantially all of the assets of the Company, or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;iii. statutory exchange of securities with another corporation (including any exchange effected in connection with a merger of a third corporation into the Company)

(any of such foregoing events contemplated by Section 5(b)(i)-(iii) inclusive being referred to herein as an "<u>Acquisition Transaction</u>") that is consummated prior to the Expiration Date, the Holder of each Warrant then outstanding will have the right thereafter to convert such Warrant into the kind and amount of shares of stock and other securities and property that the Holder would have owned or have been entitled to receive immediately after such Acquisition Transaction if the Warrant had been converted immediately prior to the effective date of the Acquisition Transaction and in any such case, if necessary, appropriate adjustment will be made in the application of the provisions set forth in this Section with respect to the rights and interests thereafter of any Holders of the Warrant, to the end that the provisions set forth in this Section will thereafter correspondingly be made applicable, as nearly as may reasonably be, in relation to any shares of stock and other securities and property thereafter deliverable on the exercise of the Warrant. The provisions of this Subsection will similarly apply to successive Acquisition Transactions unless the Company takes action under Section 5(a).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6. <u>No Voting Rights</u>. This Warrant will not entitle the Holder to any voting rights or other rights as a shareholder of the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7. <u>Notice of Transfer of Warrant or Resale of the Warrant Shares</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) The Holder, by acceptance hereof, agrees to give written notice to the Company before transferring this Warrant or transferring any Warrant Shares of Holder's intention to do so, describing briefly the manner of any proposed transfer. Promptly upon receiving such written notice, the Company will present copies thereof to the Company's counsel and to counsel to Holder of this Warrant. If in the opinion of each such counsel the proposed transfer may be effected without registration or qualification (under any federal or state securities laws), the Company, as promptly as practicable, will notify the Holder of such opinion, and the Holder will be entitled to transfer this Warrant or to dispose of Warrant Shares received upon the previous exercise of this Warrant, all in accordance with the terms of the notice delivered by the Holder to the Company; provided that an appropriate legend may be endorsed on this Warrant or the certificates for such Warrant Shares respecting restrictions upon transfer thereof necessary or advisable in the opinion of counsel to the Company and satisfactory to the Company to prevent further transfers that would be in violation of Section 5 of the Securities Act of 1933, as amended, and applicable state securities laws; and provided further that the Holder and prospective transferee or purchaser must execute such documents and make such representations, warranties, and agreements as may be required solely to comply with the exemptions relied upon by the Company for the transfer or disposition of the Warrant or Warrant Shares.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) If in the opinion of either of the counsel referred to in this Section 7, the proposed transfer or disposition of this Warrant or Warrant Shares described in the written notice given pursuant to this Section 7 may not be effected without registration or qualification of this Warrant or such Warrant Shares, the Company must promptly give written notice thereof to the Holder, and the Holder will limit its activities in respect to such as, in the opinion of both such counsel, are permitted by law.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8. <u>Fractional Shares</u>. No fractional shares will be issued upon the exercise of this Warrant, but in any <u>case</u> where the Holder would, except for the provisions of this Section, be entitled under the terms hereof to receive a fractional share, the Company will, upon the exercise of this Warrant for the largest number of whole shares then called for, pay a sum in cash equal to the sum of (i) the excess, if any, of the Fair Market Value of such fractional share over the proportional part of the Warrant Exercise Price represented by such fractional share, plus (ii) the proportional part of the Warrant Exercise Price represented by such fractional share.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9. <u>Miscellaneous; Waiver</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) The Company will not, by amendment of its Articles of Incorporation or through reorganization, consolidation, merger, dissolution or sale of assets, or by any other voluntary act or deed, avoid or seek to avoid the observance or performance of any of the covenants, stipulations or conditions to be observed or performed hereunder by the Company, but will, at all times in good faith, assist, insofar as it is able, in the carrying out of all provisions hereof and in the taking of all other action which may be necessary in order to protect the rights of the Holder hereof against dilution.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) This Warrant will be interpreted under the laws of the State of Minnesota without regard to its conflicts of laws principles. ANY ACTION BROUGHT CONCERNING THE TRANSACTIONS CONTEMPLATED BY THIS WARRANT SHALL BE BROUGHT IN THE STATE AND FEDERAL COURTS LOCATED IN THE STATE OF MINNESOTA.

IN WITNESS WHEREOF, Encore Medical, Inc., has caused this Warrant to be signed by its duly authorized officer and to be dated __________________, 202__.

---

| | |
|:---|:---|
| "Company" | "Company" |
| ENCORE MEDICAL, INC. | ENCORE MEDICAL, INC. |
| By: |  |
| Its: | Chief Executive Officer |

---

To: ENCORE MEDICAL, INC.

---

| | |
|:---|:---|
| **<u>NOTICE OF EXERCISE OF WARRANT</u>** | To Be Executed by the Registered Holder in Order to Exercise the Warrant |

---

The undersigned hereby irrevocably elects to exercise the attached Warrant to purchase for cash, __________________ of the shares issuable upon the exercise of such Warrant, and requests that certificates for such shares (together with a new Warrant to purchase the number of shares, if any, with respect to which this Warrant is not exercised) shall be issued in the name of

  <br> (Print Name)

---

| | |
|:---|:---|
| Please insert social security |  |
| or other identifying number |  |
| of registered Holder of |  |
| certificate (_____________) | Address: |
| Dated: | |
| | Signature\* |

---

\*The signature on this Notice of Exercise of Warrant must correspond to the name as written upon the face of the Warrant or the Assignment Form in every particular without alteration or enlargement or any change whatsoever. When signing on behalf of a corporation, partnership, trust or other entity, PLEASE indicate your position(s) and title(s) with such entity.

**ASSIGNMENT FORM**

To be signed only upon authorized transfer of Warrants.

FOR VALUE RECEIVED, the undersigned hereby sells, assigns, and transfers unto _______________________________ the right to purchase the securities of Encore Medical, Inc. to which the within Warrant relates and appoints ______________________, attorney, to transfer said right on the books of Encore Medical, Inc. with full power of substitution in the premises.

---

| | |
|:---|:---|
| Dated: | |
| | (Signature) |
| | Address: |

---

## Ex-Filing

?xml version='1.0' encoding='ASCII'? EX-FILING FEES

---

| |
|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Calculation of Filing Fee Tables**  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **S-1**  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Encore Medical, Inc.**  |

---

---

| | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Security Type**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Security Class Title**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Fee Calculation or Carry Forward Rule**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Amount Registered**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Proposed Maximum Offering Price Per Unit**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Maximum Aggregate Offering Price**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Fee Rate**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Amount of Registration Fee**  |
| **Newly Registered Securities** | **Newly Registered Securities** | **Newly Registered Securities** | **Newly Registered Securities** | **Newly Registered Securities** | **Newly Registered Securities** | **Newly Registered Securities** | **Newly Registered Securities** | **Newly Registered Securities** | **Newly Registered Securities** |
| Fees to be Paid | 1 | Equity | Common Stock underlying Underwriter's Warrant | 457(o) |  | $1.00 | $276000.00 | 0.0001381 | $38.12 |
| Fees Previously Paid | 2 | Equity | Common Stock, par value $0.01 per share | 457(o) | 3450000 | $5.00 | $17250000.00 |  | $2640.98 |
| Fees Previously Paid | 3 | Equity | Underwriter's Warrant | Other |  |  |  |  | $0.00 |
| Fees Previously Paid | 4 | Equity | Common Stock underlying Underwriter's Warrant | 457(o) | 276000 | $5.00 | $1380000.00 |  | $211.28 |
| **Carry Forward Securities** | **Carry Forward Securities** | **Carry Forward Securities** | **Carry Forward Securities** | **Carry Forward Securities** | **Carry Forward Securities** | **Carry Forward Securities** | **Carry Forward Securities** | **Carry Forward Securities** | **Carry Forward Securities** |
| Carry Forward Securities |  |  |  |  |  |  |  |  |  |
|  |  |  | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: |  | $18906000.00  |  | $2890.38  |
|  |  |  | Total Fees Previously Paid:  | Total Fees Previously Paid:  | Total Fees Previously Paid:  |  |  |  | $2852.26  |
|  |  |  | Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  |  |  |  | $0.00  |
|  |  |  | Net Fee Due:  | Net Fee Due:  | Net Fee Due:  |  |  |  | $38.12  |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Offering Note** <br>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <sup>1</sup> In September 2025, the Company previously paid to register the 276,000 shares underlying the underwriter's warrant at a price of $5.00 per share. Because the exercise price of the shares underlying the underwriter's warrant is equal to $6.00 per share, the Company is paying an additional registration fee for the $1.00 per share difference, which amounts to $276,000 as the maximum aggregate additional offering price. Pursuant to Rule 416 under the Securities Act, the securities being registered hereunder include such indeterminate number of additional shares of Common Stock as may be issued after the date hereof as a result of share sub-divisions, share capitalization or similar transactions.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <sup>2</sup> Represents 3,000,000 shares of Common Stock, plus an overallotment of up to 450,000 shares of Common Stock, that may be issued in the initial public offering upon exercise of the underwriter over-allotment option. Pursuant to Rule 416 under the Securities Act, the securities being registered hereunder include such indeterminate number of additional shares of Common Stock as may be issued after the date hereof as a result of share sub-divisions, share capitalization or similar transactions.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <sup>3</sup> Represents the underwriter's warrant to purchase up to 276,000 shares of Common Stock, equal to 8% of the shares of Common Stock issued in the offering, including the shares of Common Stock that may be issued in exercise of the over-allotment option. In accordance with Rule 457(g), the entire registration fee for the warrants is allocated to the shares of Common Stock underlying the warrants, and no separate fee is payable for the warrants.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <sup>4</sup> Represents shares of Common Stock underlying the underwriter's warrant to purchase up to 276,000 shares of Common Stock. Pursuant to Rule 416 under the Securities Act, the securities being registered hereunder include such indeterminate number of additional shares of Common Stock as may be issued after the date hereof as a result of share sub-divisions, share capitalization or similar transactions.

---

| |
|:---|
| |
| **Rules 457(b) and 0-11(a)(2)** |
| Fee Offset Claims |
| Fee Offset Sources |
| **Rule 457(p)** |
| Fee Offset Claims |
| Fee Offset Sources |

---